Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23338
Title: Sustained remission of Lynch syndrome-associated metastatic adrenocortical carcinoma following checkpoint inhibitor therapy-associated multiorgan autoimmunity.
Austin Authors: Nevgi, Aditi;Klein, Oliver ;Cheung, Ada S 
Affiliation: Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Endocrinology Unit, Monash Health, Clayton, Australia
Issue Date: Aug-2020
metadata.dc.date: 2020-05-25
Publication information: Clinical Endocrinology 2020; 93(2): 214-216
Abstract: Adrenocortical carcinoma (ACC) is a rare and aggressive tumour with limited treatment options for metastatic disease1 . Immunotherapy with checkpoint inhibition, in particular anti-programmed death receptor 1 (PD-1)/programmed death-ligand-1 (PD-L1) blockade has transformed the management of several malignancies. We describe prolonged remission of an ectopic-ACTH secreting refractory stage-IV ACC treated with anti-PD-1 antibody nivolumab combined with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23338
DOI: 10.1111/cen.14258
ORCID: 0000-0001-5257-5525
PubMed URL: 32449531
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Nov 30, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.